title: Fluoxetine treatment increases trabecular bone formation in mice.
abstract: Mounting evidence exists for the operation of a functional serotonin (5-HT) system in osteoclasts and osteoblasts, which involves both receptor activation and 5-HT reuptake. In previous work we showed that the serotonin transporter (5-HTT) is expressed in osteoclasts and that its activity is required by for osteoclast differentiation in vitro. The purpose of the current study was to determine the effect of treatment with fluoxetine, a specific serotonin reuptake inhibitor, on bone metabolism in vivo. Systemic administration of fluoxetine to Swiss-Webster mice for 6 weeks resulted in increased trabecular BV and BV/TV in femurs and vertebrae as determined by micro-computed tomography (microCT). This correlated with an increase in trabecular number, connectivity, and decreased trabecular spacing. Fluoxetine treatment also resulted in increased volume in vertebral trabecular bone. However, fluoxetine-treated mice were not protected against bone loss after ovariectomy, suggesting that its anabolic effect requires the presence of estrogen. The effect of blocking the 5-HTT on bone loss following an LPS-mediated inflammatory challenge was also investigated. Subcutaneous injections of LPS over the calvariae of Swiss-Webster mice for 5 days resulted in increased numbers of osteoclasts and net bone loss, whereas new bone formation and a net gain in bone mass was seen when LPS was given together with fluoxetine. We conclude that fluoxetine treatment in vivo leads to increased bone mass under normal physiologic or inflammatory conditions, but does not prevent bone loss associated with estrogen deficiency. These data suggest that commonly used anti-depressive agents may affect bone mass.
authors.affiliation: Department of Cytokine Biology, Forsyth Institute, Boston, Massachusetts 02115, USA. rbattaglino@Forsyth.org
authors.forename: R
authors.initials: R
authors.lastname: Battaglino
authors.forename: M
authors.initials: M
authors.lastname: Vokes
authors.forename: U
authors.initials: U
authors.lastname: Schulze-Späte
authors.forename: A
authors.initials: A
authors.lastname: Sharma
authors.forename: D
authors.initials: D
authors.lastname: Graves
authors.forename: T
authors.initials: T
authors.lastname: Kohler
authors.forename: R
authors.initials: R
authors.lastname: Müller
authors.forename: S
authors.initials: S
authors.lastname: Yoganathan
authors.forename: P
authors.initials: P
authors.lastname: Stashenko
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000209:etiology / Q000378:metabolism; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D005269:Femur / Q000187:drug effects / Q000378:metabolism; D005473:Fluoxetine / Q000008:administration & dosage / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D008953:Models, Anatomic; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects*; D010052:Ovariectomy / Q000009:adverse effects; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D014057:Tomography, X-Ray Computed
chemical_list: D005473:Fluoxetine; D008070:Lipopolysaccharides; D017367:Selective Serotonin Reuptake Inhibitors